Cyrille Hulin

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Thierry Façon, Shaji Kumar, Torben Plesner et al. · New England Journal of Medicine · 2019 · 987 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

Michel Attal, Thierry Façon, François Guilhot et al. · New England Journal of Medicine · 2003 · 974 citations

Medicine, Oncology, Radiation Oncology +17

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 953 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros et al. · The Lancet Oncology · 2019 · 796 citations

Medicine, Pharmacology, Pharmacotherapy +11

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Lotfi Benboubker, Meletios Α. Dimopoulos, Angela Dispenzieri et al. · New England Journal of Medicine · 2014 · 786 citations · Full text

Medicine, Oncology, Pharmacotherapy +11